National Research Co. (NASDAQ:NRC) CFO Kevin R. Karas sold 2,902 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $62.83, for a total transaction of $182,332.66.
Shares of NASDAQ:NRC opened at $61.73 on Friday. The company has a market cap of $1.53 billion, a price-to-earnings ratio of 59.36 and a beta of 0.82. The company has a 50-day moving average price of $49.80 and a 200-day moving average price of $36.28. The company has a current ratio of 0.62, a quick ratio of 0.62 and a debt-to-equity ratio of 1.24. National Research Co. has a 12 month low of $35.58 and a 12 month high of $68.86.
National Research (NASDAQ:NRC) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.26 by $0.03. The firm had revenue of $31.41 million during the quarter, compared to the consensus estimate of $30.26 million. National Research had a net margin of 24.59% and a return on equity of 124.11%.
Several large investors have recently modified their holdings of NRC. Quantamental Technologies LLC raised its stake in shares of National Research by 125.2% during the second quarter. Quantamental Technologies LLC now owns 743 shares of the company’s stock valued at $43,000 after acquiring an additional 413 shares during the last quarter. Bank of Montreal Can bought a new position in shares of National Research during the second quarter valued at about $59,000. BNP Paribas Arbitrage SA raised its stake in shares of National Research by 10,395.5% during the first quarter. BNP Paribas Arbitrage SA now owns 2,309 shares of the company’s stock valued at $89,000 after acquiring an additional 2,287 shares during the last quarter. Advisor Group Inc. raised its stake in shares of National Research by 17.8% during the second quarter. Advisor Group Inc. now owns 2,263 shares of the company’s stock valued at $131,000 after acquiring an additional 342 shares during the last quarter. Finally, Aperio Group LLC bought a new position in shares of National Research during the second quarter valued at about $176,000. 36.03% of the stock is owned by hedge funds and other institutional investors.
National Research Company Profile
National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company’s portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement.
Featured Article: Technical Indicators – What is a Golden Cross?
Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.